Erste Group analyst Hans Engel downgraded Amgen (AMGN) to Hold from Buy. The company’s planned weight loss products are still in the clinical trial phase and are only likely to make moderate contributions to sales growth in the coming years, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen says MHRA granted marketing authorization to Tepezza for TED
- Amgen price target raised to $280 from $235 at Mizuho
- Amgen’s Mixed Financial Outlook: Strong Q1 Performance but Cautious Future Guidance Leads to Hold Rating
- Amgen’s Strong Financial Performance and Strategic Positioning Earns Buy Rating from Analyst
- Amgen Inc. Reports Strong Growth Amid Challenges